WO2000001813A2 - Peptide inhibitors of androgen-independent activation of androgen receptor - Google Patents
Peptide inhibitors of androgen-independent activation of androgen receptor Download PDFInfo
- Publication number
- WO2000001813A2 WO2000001813A2 PCT/CA1999/000604 CA9900604W WO0001813A2 WO 2000001813 A2 WO2000001813 A2 WO 2000001813A2 CA 9900604 W CA9900604 W CA 9900604W WO 0001813 A2 WO0001813 A2 WO 0001813A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- androgen
- peptide
- amino acids
- tracts
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- Various diseases have an androgen mediated aspect, including prostate cancer, benign prostatic hyperplasia, hirsutism, androgenic alopecia, acne, breast cancer and Kennedy disease.
- Androgen deprivation aimed at inducing the death of androgen-dependent tumor cells is a potential treatment for such "androgen mediated diseases" and is the only useful systemic therapy available for prostate cancer in humans.
- the treatment involves surgical castration of the patient or treatment with anti-androgen drugs or drugs that inhibit production of androgens.
- the inability of androgen deprivation to eliminate all prostate cancer cell populations in a patient is manifested by a predictable pattern of response to the treatment.
- Initial therapy-induced regression of the malignancy is usually followed by a relapse with ultimate progression to complete resistance to further hormonal manipulations. This progression is the result of adaptation of surviving tumor cells to diminishing levels of androgen or outgrowth of subpopulations of androgen-independent tumor cells.
- Androgen independence appears to involve changes in androgen receptor regulated gene transcription.
- the androgen receptor (AR) as a transcription factor forms the basis of a signal transduction pathway that regulates the expression of certain androgen- responsive genes.
- Control of androgen responsive gene activity may be agonistic (stimulated) or antagonistic (repressed) and results from binding of androgen- activated AR to upstream flanking nucleotide sequences, termed androgen response elements (AREs).
- AREs upstream flanking nucleotide sequences
- the AR is activated (transformed) by androgens, including the naturally occurring androgenic hormones testosterone and dihydrotestosterone, as well as synthetic androgens such as R1881.
- AR from various mammalian sources has been isolated and characterized. As well, various assays for AR are known.
- the deduced amino acid sequence of human AR has been reported (1) as have DNA sequences encoding human and rat AR and cells transformed with such sequences (2, 3 10).
- Androgen activation of AR is mediated by ligand (androgen) binding to a ligand binding domain (LBD) located in the carboxy-terminus of the AR.
- LBD ligand binding domain
- the LBD is in the region of amino acids 671-919.
- Certain anti-androgen compounds are also known to bind to the LBD.
- Androgen induced activation of the AR is associated with conformation of the AR becoming more compact upon ligand binding, heatshock proteins being dissociated, and dimerization and phosphorylation occurring prior to DNA-binding.
- the DNA-binding domain is centrally located in AR.
- the DBD is in the region of amino acids 557-622.
- the N-terminus region preceding the DBD contributes to DNA-binding as well as transcriptional activation or repression (11).
- Expression of various N-terminal AR deletion and insertion mutants lacking a LBD but comprising the AR DBD as well as co-expression of various AR N-terminal fragments fused to a heterologous DBD (GAL4) with a GAL4 responsive reporter demonstrates the presence of transcription activation domains in the first 485 amino acids and in the region of amino acids 360-528 of human AR (12).
- AR belongs to the superfamily of nuclear receptors that mediate actions of lipophilic ligands, including steroids, retinoids, vitamin D3, and thyroid hormones. These receptors have distinct functional domains that include a carboxy-terminal LBD, a highly conserved DBD comprised of two zinc finger motifs, and a poorly conserved amino-terminal domain that may contain several transcriptional activation or repression domains. In all cases, binding of ligand to the receptor results in activation, such that the receptor can effectively bind to its specific DNA element.
- Estrogen and progesterone receptors belong to the same family of ligand-activated transcription factors as the AR.
- the former receptors can be activated in the absence of their respective ligands.
- the estrogen receptor for example, can be activated through three different signaling events, i.e. not only by estrogens, but also by cAMP or by a growth factor (e.g., epidermal growth factor), each of these compounds acting via a different domain of the receptor.
- the AR can also be activated in the absence of androgen by elevation of cyclic AMP (cAMP) levels and by growth factors (4-6, 8). Phosphorylation has been implicated in the ligand- independent activation of the progesterone, estrogen, and retinoic acid receptors.
- phosphorylation does not appear to be essential for the induction of androgen-regulated genes (7) and phosphorylation does not alter activity.
- Androgen-independent activation of the AR involving cAMP-dependent protein kinase A (PKA) signal transduction pathways has been observed (6).
- PKA protein kinase A
- One of the inventors named herein has determined that exposing prostate cells to forskolin (an activator of PKA) in the absence of androgen, leads to activation of the promoter of the prostate specific antigen (PSA) gene, a process shown to be mediated by the AR (9).
- PSA is a clinically important androgen-stimulated gene which is used to monitor treatment responses, prognosis and progression in patients with prostate cancer.
- Expression of PSA is initially androgen-regulated and undergoes a sharp decline following medical or surgical castration.
- PSA mRNA is constitutively up-regulated (9).
- the promoter and enhancer regions of the PSA gene have been sequenced as far as -5824 from the start site of transcription and the following DNA response elements have been characterized: TATA box , -28 to -23; androgen response elements (AREs), -170 to - 156, -4148 to -4134; and, androgen response region (ARR), -395 to -376.
- the inventors have found that interaction of the AR with the PKA pathway involves a discrete region of the N-terminal domain of the AR (amino acid region 234-391). This region is also involved in androgen-independent activation of the AR resulting from treatment with a differentiating agent (butyrate).
- This invention now provides the means for generation of small molecules (including peptides and peptide mimetics) for inhibiting androgen-independent activation of the human AR.
- Such inhibitory compounds, used in combination with androgen deprivation would more effectively limit androgen mediated disease progression.
- This invention provides a non-androgen ligand binding peptide comprising one or more tracts of amino acids derived from at least 10 contiguous amino acids of amino acids 234-391 of human AR, providing that said peptide does not contain a DNA-binding domain.
- Peptides of this invention will comprise one or more tracts of amino acids derived from preferably at least 20, and more preferably at least 30, even more preferably at least 50 and even more preferably at least 100 contiguous amino acids derived from amino acids 234-391 of human AR.
- the tract of amino acids may be substantially identical to amino acids 234-391 of human AR.
- Peptides of this invention may comprise AR derived amino acids substantially consisting of only the aforesaid tracts of amino acids.
- Peptides of this invention may substantially consist of the aforesaid tracts of amino acids or may comprise additional amino acids. Where a peptide comprises AR derived amino acids substantially consisting of one or more of the aforesaid tracts, the peptide may additionally comprise a DNA-binding domain.
- This invention also provides nucleic acid constructs encoding peptides of this invention as well as said constructs in an expression vector.
- This invention also provides cells and pharmaceutical compositions comprising the peptides, nucleic acid constructs and expression vectors of this invention.
- This invention also provides a method of inhibiting androgen-independent activation of AR by introducing into said cell, a peptide, nucleic acid construct or expression vector of this invention.
- This invention also provides the use of a peptide, nucleic acid construct, expression vector or cell of this invention for the preparation of a medicament for the treatment of androgen mediated diseases including prostate tumors.
- This invention also provides the use of a peptide, nucleic acid construct, expression vector or pharmaceutical composition of this invention for treatment of androgen mediated diseases including prostate tumors, particularly in patients undergoing androgen deprivation therapy.
- This invention also provides a method of determining whether a compound or a mixture of compounds affects androgen-independent activation of androgen receptor (AR) comprising the steps of:
- said one or more tracts of amino acids may be derived from differing lengths of contiguous amino acids of amino acids 234-391, as described above for the peptides of this invention.
- FIG. 1 is a schematic showing a general scheme for preparation of a reporter, as well as expression vectors encoding AR proteins fused to the GAL4 DBD.
- FIG. 2 is a graph showing that the amino-terminus of the AR is activated by forskolin as manifested by Gal4-luciferase activity.
- Transactivation assays were performed in LNCaP cells transfected with a 5xGal4UAS-TATA-luciferase reporter, Gal4DBD, and AR N -Gal4 DBD and exposed to R1881 or forskolin (aPKA).
- FIG. 3 is a schematic showing chimeric expression vectors consisting -of GAL4-DBD DNA sequences fused to DNA sequences encoding various sections of the N-terminal domain of AR.
- FIG. 4 is a graph showing GAL4 luciferase activity in cells transfected with the expression vectors shown in Fig. 3 and a plasmid containing the reporter shown in Fig. 1. The cells were exposed to the PKA catalytic domain (A) and butyrate (B).
- FIG. 5 is a schematic showing identification of a protein(s) interacting with the 234-391 amino acid region of the AR during androgen-independent activation of the human AR.
- FIG. 6 is a schematic showing two ways by which small molecules inhibit the interaction of the 234-391 amino acid region of AR with activating agents involved in androgen-independent activation of AR.
- FIG. 7 is a graph showing inhibition of forskolin (FSK) mediated stimulation of PSA luciferase activity by a vector expressing a N-terminal domain of AR.
- FSK forskolin
- amino acid sequence of the human AR as determined by Lubahn et at. (1), is given below.
- non-androgen ligand binding peptide means a peptide capable of binding to a ligand other than androgen.
- tract(s) of amino acids is a sequence of two or more amino acids joined by peptide bonds.
- peptide means a compound comprising at least two amino acids joined by peptide bonds and includes a polypeptide and a protein, and peptides that comprise non-naturally occuring amino acids and peptide linkages.
- DNA-binding domain is a tract of amino acids capable of binding to DNA in a regulatory element of a gene. Examples include the androgen receptor DBD which bind to regulatory elements of androgen sensitive genes. In the case of PSA, the DBD binds to an ARE region of the PSA promoter.
- the DBD of GAL4 is an example of a yeast DBD used in the commercial reporter systems in which expression of the reporter is activated or repressed by a moiety joined to the GAL4 DBD and brought into close proximity with a regulatory element (eg. promoter) of the reporter when the DBD binds to the reporter.
- nucleic acid means DNA or RNA.
- a nucleic acid encoding a peptide is a nucleic acid containing or corresponding to a sequence of nucleotides, which sequence when transcribed and translated (or simply translated in the case-of RNA) would result in the peptide.
- the term is meant to include any such sequence of nucleotides which, because of the degeneracy of the nucleic acid code, will encode (or corresponds to a sequence which will encode) the peptide as described above.
- a nucleic acid which corresponds to a sequence encoding a peptide is a nucleic acid that is complementary to a coding sequence. Nucleic acids of this invention may include anti-sense molecules where inhibition of expression of the peptides is desired.
- the term 'expression vector is a nucleic acid construct including a plasmid, phage genome or other nucleic acid which is able to replicate in a host cell and which contains a nucleic acid sequence encoding a desired peptide product.
- the nucleic acid sequence encoding the peptide will be expressed in the host cell.
- the vector may include elements necessary for incorporation of the encoding sequence into a host cell genome and the vector will contain regulatory elements operably linked to the coding sequence to permit expression of the gene product in the host cell.
- the term "derived from" with reference to an amino acid sequence means that a first sequence of amino acids is substantially identical to a reference sequence of amino acids.
- androgen receptor derived amino acids means those parts of a peptide consisting of at least 10 contiguous amino acids which are substantially identical to a tract of 10 or more amino acids in androgen receptor.
- a peptide that comprises androgen receptor derived amino acids substantially consisting of a specified tract of amino acids is a peptide in which the only tract substantially identical to a tract of amino acids in androgen receptor is the specified tract.
- the peptide may also contain tracts of amino acids not substantially identical to tracts of amino acids in androgen receptor or the peptide may consist substantially of only of tracts substantially identical to androgen receptor.
- substantially identical with reference to peptides of this invention or used in this invention refers to first and reference sequences which have at least one function of a peptide of this invention in common and having at least 75% identity (more preferably at least 90% identity) as determined by comparing positions in each sequence.
- Sequence identity may be determined by the BLAST algorithm described in Altschul et al. (1990) J. Mol. Biol. 215:403-410, using the published default settings. When a position in the compared sequence is occupied by the same amino acid, the molecules are considered to have shared identity at that position.
- the degree of identity between sequences is a function of the number of matching positions shared by the sequence.
- derived from is meant to include situations where conservative substitutions, deletions or additions are made in a first sequence of amino acids relative to a reference sequence. Examples of such conservative changes are the substitution of amino acids having similar "side" or “functional” groups, preferably similar in charge and ligand reactivity; most preferably also similar in size.
- a tract of amino acids derived from a specified number of contiguous amino acids of a reference sequence may or may not have the same number of and exact sequence of the specified contiguous amino acids of the reference, providing the tract and the specified amino acids of the reference are substantially identical as defined herein.
- Nucleic acids of this invention may be synthesized when convenient or may be produced by recombinant techniques known in the art.
- Nucleic acids within the scope of this invention may contain linkers, modified or unmodified restriction endonuclease sites and other sequences of nucleotides useful for cloning, expression, or purification. Nucleic acids within the scope of this invention may be incorporated in a larger sequence of nucleotides, including plasmids and vectors useful for manipulation or expression of nucleic acids.
- Peptides of this invention may be synthesized when convenient by any number of known peptide synthesis techniques.
- the peptides may be expressed in any suitable host cell into which an expression vector for the peptide has been introduced.
- the host cell and expression vector components will typically be selected to allow for expression of the peptide in the host.
- Any peptide of this invention may comprise multiple (eg. repeat) tracts of amino acids derived from SEQ ID NO:l which may enhance the activity of the peptide.
- Peptides of this invention are useful as having one or more of the following functions: an agent for inhibiting androgen dependent activation of the AR; -an activation domain; and, a tool for screening compounds which affect androgen- dependent activation of AR. Examples whereby peptides of this invention are tested or used for such functions are set out below.
- the peptides will typically lack an intact or functional DBD, in particular a DBD that is capable of binding to an androgen sensitive gene.
- the peptide might include other portions of the AR including the LBD (which will not be effective absent a functional androgen receptor DBD).
- peptides of this invention used for inhibiting androgen independent activation of AR will substantially consist of androgen receptor derived amino acids which are derived only from SEQ ID NO: 1.
- peptides of this invention may include a DBD if DNA-binding is desirable in the chosen mode of screening.
- the mode of screening involves monitoring a change in pattern of activation or repression of a gene by the peptide when affected by a test compound (thereby necessitating the inclusion of DBD on the peptide)
- the peptide will not have an AR LBD so as to avoid an erroneous response brought about by ligand binding to the LBD.
- Methods of this invention for determining whether a compound affects androgen-dependent activation of the AR may be used to detect compounds that potentially inhibit or bring about activation of the AR.
- this method involves determining whether a compound binds to amino acid tracts derived from SEQ ID NO: 1. This may be accomplished by a variety of known methods which may also facilitate the separation and recovery of the binding compound. Detection of an apparent change in conformation or molecular weight of a peptide when bound to a compound may be carried out, for example by gradient ultra-centrifugation or by SDS PAGE.
- the peptide could be labeled (for example by a fluorescent compound) to facilitate separation.
- the peptide could be immobilized to facilitate separation of binding compounds. An example of such immobilization is attachment of the peptide to a suitable activated substrate (eg. beads of a chromatography gel), or by immunological techniques.
- Antibodies to AR and methods of producing anti-AR antibodies have been described (2, 12).
- Alternate methods of screening which are part of this invention involve monitoring a change in the function of a peptide of this invention.
- one may take advantage of the transactivation/repression characteristics of the N-terminal region of the AR and employ methods whereby enhancement or repression of such characteristics are observed as being indicative of the presence of a compound that interact with the peptide in such a way as to affect such characteristics.
- cells may be prepared which express a chimeric protein consisting of an AR N-terminal portion including a tract derived from SEQ ID NO: 1 , joined to a DBD.
- the DBD is a "label" as the term is used herein.
- the reporter could be an androgen sensitive gene whose product is measurable or the reporter could be part of a construct intended to produce a readily detectable signal (such as the luciferase reporter used in the examples herein).
- a measurable androgen sensitive gene product is PSA and methods for detecting expression of PSA immuno logically or by monitoring PSA mRNA are known. In the latter case, the protein "labeled" with the DBD will either not contain an AR LBD or the cells will be deprived of androgen (the cells will not contain endogenous androgen and no androgen will be applied to the cells).
- compositions of this invention will typically comprise a peptide of this invention as an active ingredient and a pharmaceutically acceptable carrier.
- the carrier will be one which will facilitate delivery of the peptide into afflicted cells such as those of a prostate tumor.
- Suitable carriers for injection or diffusion of the peptide into a tumor would include traditional vehicles such as saline, as well as more complex formulations such as liposome formulations and nonrecombinant viral vectors such as was described by Nazareth, et al. (6).
- pharmaceutical compositions of this invention may include "gene therapy" vectors such as recombinant adenovirus for delivery and replication of an expression vector capable of producing a peptide of this invention.
- GAL4 yeast transcription factor
- GAL4 consists of two well-defined domains, i.e. an activation domain and a DNA-binding domain.
- Chimeric proteins were generated by substituting the activation domain of GAL4 by one of a number of sections of the N-terminal region of the human AR. While these chimeric proteins had a DNA-binding site located in their GAL4 segment, they did not have the LBD of AR.
- expression vectors were constructed as described below, consisting of DNA encoding the DNA-binding domain (DBD) of GAL4 (supplied by Clontech) fused to DNA encoding various regions of the AR: i.e.
- a luciferase reporter vector consisting of the luciferase gene and the GAL4 DNA response element located upstream of the luciferase gene, was used for assessing activation of transcriptional activity of the chimeric proteins.
- Another vector, containing the catalytic domain of PKA (Clontech) was used to induce PKA signaling.
- luciferase activity in cell lysates was assayed as described below. All chemicals were purchased from Sigma (St. Louis, MO), unless stated otherwise.
- PC3 cells between the 30 l and 45' generation were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum (FBS) (GIBCO/BRL, Burlington, Ontario, Canada).
- LNCaP cells between the 44 th and 55 th generation were maintained in RPMI 1640 supplemented with 5% FBS. When the plates or wells were 60-70% confluent with cells, the culture medium was changed to serum-free medium containing vehicle (DMSO), R1881, or forskolin.
- DMSO serum-free medium containing vehicle
- the AR N Gal4 plasmid was constructed by PCR amplification of the nucleotides 363 to 2039 of human AR cDNA using primers 5'-AAA GGA TCC GGA TGG AAG TGC AGT TAG GGC T (SEQ ID NO: 3) and 5'-AAA AGG ATC CTT CAG GTC TTC TGG GGT GGA AAG TAA TAG (SEQ ID NO:4).
- the amplified DNA fragment was purified, blunt-end ligated into the EcoRV site of Bluescript SK(-) excised with BamRI and cloned into the Bam ⁇ U. site of pFA-CMV plasmid (Stratagene Cloning System, La Jolla, CA).
- constructs containing different AR N-terminal domains were prepared. The orientation and sequences were confirmed by DNA sequence analysis and expressed protein was detected by Western blotting.
- An expression vector for the catalytic subunit of protein kinase A (PKAc) was purchased from Stratagene (PathDetect CREB trans-Reporting System).
- LNCaP cells (3 x 10 5 ) were plated on 6-well plates and incubated in RPMI 1640 with 5% FBS prior to transfection. Total amount of plasmid DNA used was typically normalized to 3 ⁇ g/well by the addition of empty plasmid. Medium was replaced after 24 h by serum-free RPMI 1640 containing variously, DMSO, R1881, or forskolin. Cells were collected after 48 h incubation.
- PC3 cells (3 x 10 5 ) between the 30 th and 45 th generation, were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum (FBS) (GIBCO/BRL, Burlington, Ontario, Canada). Total amount of plasmid DNA used was typically normalized to 3 ⁇ g/well by the addition of empty plasmid. Cells were transfected in serum-free conditions for 5 h and then incubated with forskolin (FSK, 50 ⁇ M), R1881 (10 nM), or vehicle (DMSO, 0.5%), for an additional 16 h under serum-free conditions before harvesting.
- DMEM Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- Luciferase activities in cell lysates were measured using the Dual Luciferase Assay System (Promega, Madison, WI). Luciferase activities were normalized by the Renilla activities and protein concentrations of the samples. The results were converted to fold-induction, which is the relative luciferase activity of the treated cells over that of the control cells, or activity in the presence of a stimulus over activity absent stimuli.
- Amino terminal fragments containing approximately amino acids 1-559 (AR N ) of the human AR were cloned into the carboxyl terminus of Gal4 DBD.
- Expression vectors for these chimeric proteins were cotransfected into LNCaP cells with the above-described reporter gene which contains the Gal4-binding site as a c ⁇ -acting element (p5xGal4UAS-TATA-luciferase).
- LNCaP cells express endogenous AR and PSA. As shown in Fig. 2, the synthetic androgen R1881 did not significantly change the activity of the reporter when comparing AR N Gal4DBD (lane 4) to Gal4DBD lacking the amino-terminus of the AR (lane 3).
- PC3 cells are of human prostate cancer origin but are poorly differentiated and do not express AR or PSA. This activation was localized to amino acid region 234-391, since only constructs containing this amino acid region (1-558, 234-391 and 1-391) showed enhanced induction. Furthermore, constructs not containing amino acid region 234-391 (i.e. 1-233 and 392-558) did not increase induction above that obtained with a construct containing only the GAL4 DNA-binding site (GAL4-DBD). Thus, non-androgen activation is confined to amino acid region 234-391 of the AR.
- Figure 5 shows an example procedure for identification of proteins interacting with amino acid region 234-391 of the AR during its androgen-independent activation.
- cells are transfected with e.g., a GAL4-AR234-391 plasmid construct, and then exposed to stimuli.
- the cells are then lysed and the GAL4-AR fusion protein is precipitated with an antibody specific for the GAL4 segment of the chimeric protein. If, as a result of stimulation, a protein(s) binds to the expressed 234-391 region of the AR, it will be co-precipitated along with the GAL4-AR fusion protein and may be detected as an additional protein band on an SDS polyacrylamide gel. Recovery and characterization of the protein could then be done using standard procedures.
- Figure 6 shows two mechanisms by which small molecules (e.g., peptides, peptide mimetics) would inhibit the interaction of the 234-391 amino acid region of the AR with activating agents (proteins).
- small molecules e.g., peptides, peptide mimetics
- activating agents proteins
- a small molecule binds to the 234-391 region of the AR and as a result, prevents activation.
- compounds mimicking the 234-391 region of the AR in terms of amino acid sequences or active sites
- the first category of inhibitory compounds may be developed, for example, using a phage display method based on the binding of small peptides from a combinatorial phage library to a recombined "bait" protein, containing the 234-391 amino acid region of the human AR or sections thereof (eg. 10-20 mer sections).
- Phage display protein ligand screening systems are described by Lowman, H B. et al, Biochem. 30:10832-10838 (1991); Markland, W. et al, Gene 109:13-19 (1991); Roberts, B. L. et al., Proc. Natl. Acad. Sci. (U.S.A.) 89:2429-2433 (1992); Smith, G.
- this method involves expressing a fusion protein in which a putative ligand for the "bait" is fused to the N-terminus of a viral coat protein (such as the Ml 3 Gene III coat protein, or a lambda coat protein).
- a viral coat protein such as the Ml 3 Gene III coat protein, or a lambda coat protein.
- a library of phage are engineered to display putative peptide ligands on the coat protein. The phage are placed in contact with the bait. Phage that display coat protein having peptides that are capable of binding to the bait are immobilized by such treatment, whereas all other phage can be washed away.
- the bound phage can be amplified, and the DNA encoding their respective coat proteins is sequenced. In this manner, the amino acid sequence of peptides that bind to the "bait" can be deduced.
- the second category of inhibitors could be developed by examining the inhibitory effect on non-ligand activation of the GAL4-AR234-391 chimeric protein of short peptides (10-20 mer length) which encode fragments of amino acid region 234-391 of the human AR.
- potentially inhibitory peptides could be introduced into the cells in the form of expression vectors encoding the sequences of the peptides. Animal tumor models are available for in vivo testing of identified inhibitory compounds.
- Androgen-independent AR expression of the prostate specific antigen (PSA) gene can be obtained in cultured LNCaP human prostate cancer cells by incubating the cells with forskolin, an activator of PKA (9).
- a luciferase reporter vector consisting of the PSA promoter located upstream of the luciferase gene, was used for assessing androgen-independent activation of the PSA gene.
- PSA promoter plasmid PSA 5' flanking DNA (-630/+12) was obtained by PCR amplification of human genomic DNA using oligonucleotide primers corresponding to the PSA gene and ligated with Ec Rv-digested pBluescriptTM (pBS) sk(-) (Stratagene, La Jolla, CA, USA) according to a method previously described (10).
- pBS Ec Rv-digested pBluescriptTM
- a chimeric protein was generated by inserting the N-terminal region [amino acids 1 to 558] of the human AR into a His-tag expression vector (In Vitrogen).
- the expression vector (1-558) or the vector with no N-terminal domain (HisTag) were co-transfected with the PSA-luciferase reporter into LNCaP human prostate cancer cells and incubated without androgens in the presence or absence of forskolin.
- the luciferase reporter without the PSA promoter pGL2 was also co-transfected into LNCaP cells.
- FIG 7 shows non-ligand activation of AR by forskolin (PKA stimulation) (HisTag+PSA).
- PKA stimulation forskolin
- HisTag+PSA the empty vector
- pGL2 vector Expression of the pGL2 vector does not increase upon addition of forskolin showing that activation is dependent upon the PSA promoter
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002302169A CA2302169A1 (en) | 1998-06-30 | 1999-06-30 | Inhibitors of androgen-independent activation of androgen receptor |
AU44943/99A AU4494399A (en) | 1998-06-30 | 1999-06-30 | Inhibitors of androgen-independent activation of androgen receptor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9187198P | 1998-06-30 | 1998-06-30 | |
US60/091,871 | 1998-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000001813A2 true WO2000001813A2 (en) | 2000-01-13 |
WO2000001813A3 WO2000001813A3 (en) | 2000-04-13 |
Family
ID=22230037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/000604 WO2000001813A2 (en) | 1998-06-30 | 1999-06-30 | Peptide inhibitors of androgen-independent activation of androgen receptor |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4494399A (en) |
CA (1) | CA2302169A1 (en) |
WO (1) | WO2000001813A2 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1270591A1 (en) * | 2001-06-25 | 2003-01-02 | Okazaki National Research Institutes | Transgenic cells and a method for detecting disruptors for androgens by using said transgenic cells |
WO2008113770A2 (en) * | 2007-03-16 | 2008-09-25 | Cancer Research Technology Ltd | Anti-androgen peptides and uses thereof in cancer therapy |
WO2009135907A1 (en) * | 2008-05-07 | 2009-11-12 | Galderma Research & Development | Adfp modulators in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoea |
WO2010000066A1 (en) | 2008-07-02 | 2010-01-07 | British Columbia Cancer Agency Branch | Diglycidic ether derivative therapeutics and methods for their use |
WO2010020055A1 (en) | 2008-08-22 | 2010-02-25 | British Columbia Cancer Agency Branch | Small molecule inhibitors of n-terminus activation of the androgen receptor |
US20100291086A1 (en) * | 2007-09-11 | 2010-11-18 | Christopher Hovens | Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers |
WO2012139039A2 (en) | 2011-04-08 | 2012-10-11 | British Columbia Cancer Agency Branch | Bisphenol compounds and methods for their use |
WO2013028572A1 (en) | 2011-08-19 | 2013-02-28 | British Columbia Cancer Agency Branch | Fluorinated bisphenol ether compounds and methods for their use |
WO2013064830A2 (en) * | 2011-11-01 | 2013-05-10 | Valirx Plc | Medical use |
US9173939B2 (en) | 2013-05-10 | 2015-11-03 | The University Of British Columbia | Ester derivatives of androgen receptor modulators and methods for their use |
WO2015184393A1 (en) | 2014-05-30 | 2015-12-03 | British Columbia Cancer Agency Branch | Androgen receptor modulators and methods for their use |
US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
US9375496B2 (en) | 2013-09-09 | 2016-06-28 | British Columbia Cancer Agency Branch | Halogenated compounds for cancer imaging and treatment and methods for their use |
US9388112B2 (en) | 2010-01-06 | 2016-07-12 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
WO2016112455A1 (en) | 2015-01-13 | 2016-07-21 | British Columbia Cancer Agency Branch | Heterocyclic compounds for cancer imaging and treatment and methods for their use |
WO2017177307A1 (en) | 2016-04-15 | 2017-10-19 | British Columbia Cancer Agency Branch | Bisphenol derivatives and their use as androgen receptor activity modulators |
CN110072879A (en) * | 2016-08-08 | 2019-07-30 | 奥利通公司 | Androgen receptor antisense oligonucleotides |
US10400008B2 (en) | 2013-05-01 | 2019-09-03 | Cancer Research Technology Limited | Modulators of the SRC-kinase activity for preventing or treating metastatic cancer |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
US11059795B2 (en) | 2018-10-18 | 2021-07-13 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
US11242324B2 (en) | 2020-04-17 | 2022-02-08 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
WO2023046283A1 (en) | 2021-09-22 | 2023-03-30 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989009791A1 (en) * | 1988-04-14 | 1989-10-19 | University Of North Carolina At Chapel Hill | Dna encoding androgen receptor protein |
EP0577932A2 (en) * | 1992-05-08 | 1994-01-12 | American Cyanamid Company | Development of a mechanism-based screen to identify androgen receptor agonists and antagonists |
WO1997030074A1 (en) * | 1996-02-16 | 1997-08-21 | Cytogen Corporation | Isolation and use of sh3 binding peptides |
-
1999
- 1999-06-30 AU AU44943/99A patent/AU4494399A/en not_active Abandoned
- 1999-06-30 CA CA002302169A patent/CA2302169A1/en not_active Abandoned
- 1999-06-30 WO PCT/CA1999/000604 patent/WO2000001813A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989009791A1 (en) * | 1988-04-14 | 1989-10-19 | University Of North Carolina At Chapel Hill | Dna encoding androgen receptor protein |
EP0577932A2 (en) * | 1992-05-08 | 1994-01-12 | American Cyanamid Company | Development of a mechanism-based screen to identify androgen receptor agonists and antagonists |
WO1997030074A1 (en) * | 1996-02-16 | 1997-08-21 | Cytogen Corporation | Isolation and use of sh3 binding peptides |
Non-Patent Citations (7)
Title |
---|
CHAMBERLAIN, N L ET AL., : "Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 43, 25 October 1996 (1996-10-25), pages 26772-26778, XP002130096 * |
CULIG Z ET AL., : "Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor" CANCER RESEARCH, vol. 54, 15 October 1994 (1994-10-15), pages 5474-5478, XP000867802 cited in the application * |
DE RUITER PE ET AL., : "Synergism between androgens and protein kinase-C on androgen regulated gene expression" MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 110, 1995, pages r1-r6, XP000874779 * |
JENSTER G ET AL., : "Identification of two transcription activation units in the N-terminal domain of the human androgen receptor." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 13, 31 March 1995 (1995-03-31), pages 7341-7346, XP000867758 cited in the application * |
JIA L D ET AL: "Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells" STEROIDS: STRUCTURE, FUNCTION, AND REGULATION,US,ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 61, no. 9, 1996, page 531-539 XP004070285 ISSN: 0039-128X * |
NAZARETH LV AND WEIGEL NL: "Activation of human androgen receptor through a protein kinase A signaling pathway" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, 1996, pages 19900-19907, XP002130095 cited in the application * |
SADAR MD: "Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 12 March 1999 (1999-03-12), pages 7777-7783, XP002130097 cited in the application * |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1270591A1 (en) * | 2001-06-25 | 2003-01-02 | Okazaki National Research Institutes | Transgenic cells and a method for detecting disruptors for androgens by using said transgenic cells |
WO2008113770A2 (en) * | 2007-03-16 | 2008-09-25 | Cancer Research Technology Ltd | Anti-androgen peptides and uses thereof in cancer therapy |
WO2008113770A3 (en) * | 2007-03-16 | 2009-02-12 | Cancer Rec Tech Ltd | Anti-androgen peptides and uses thereof in cancer therapy |
JP2014087363A (en) * | 2007-03-16 | 2014-05-15 | Cancer Research Technology Ltd | Anti-androgen peptide and use thereof in cancer treatment |
JP2016175927A (en) * | 2007-03-16 | 2016-10-06 | キャンサー・リサーチ・テクノロジー・リミテッドCancer Research Technology Limited | Anti-androgen peptides and uses thereof in cancer therapy |
US9919023B2 (en) | 2007-03-16 | 2018-03-20 | Cancer Research Technology Limited | Anti-androgen peptides and uses thereof in cancer therapy |
EP3412685A1 (en) | 2007-03-16 | 2018-12-12 | Cancer Research Technology Ltd. | Anti-androgen peptides and uses thereof in cancer therapy |
JP2010521441A (en) * | 2007-03-16 | 2010-06-24 | キャンサー・リサーチ・テクノロジー・リミテッド | Antiandrogenic peptides and their use in cancer therapy |
US11560406B2 (en) | 2007-03-16 | 2023-01-24 | Cancer Research Technology Limited | Anti-androgen peptides and uses thereof in cancer therapy |
AU2008228274B2 (en) * | 2007-03-16 | 2013-04-18 | Cancer Research Technology Ltd | Anti-androgen peptides and uses thereof in cancer therapy |
US20100291086A1 (en) * | 2007-09-11 | 2010-11-18 | Christopher Hovens | Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers |
WO2009135907A1 (en) * | 2008-05-07 | 2009-11-12 | Galderma Research & Development | Adfp modulators in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoea |
EP3252032A1 (en) | 2008-07-02 | 2017-12-06 | British Columbia Cancer Agency Branch | Diglycidic ether derivative therapeutics and methods for their use |
US9862667B2 (en) | 2008-07-02 | 2018-01-09 | The University Of British Columbia | Diglycidic ether derivative therapeutics and methods for their use |
WO2010000066A1 (en) | 2008-07-02 | 2010-01-07 | British Columbia Cancer Agency Branch | Diglycidic ether derivative therapeutics and methods for their use |
US8686050B2 (en) | 2008-07-02 | 2014-04-01 | The University Of British Columbia | Diglycidic ether derivative therapeutics and methods for their use |
US9487479B2 (en) | 2008-08-22 | 2016-11-08 | The University Of British Columbia | Small molecule inhibitors of N-terminus activation of the androgen receptor |
WO2010020055A1 (en) | 2008-08-22 | 2010-02-25 | British Columbia Cancer Agency Branch | Small molecule inhibitors of n-terminus activation of the androgen receptor |
FR2938334A1 (en) * | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | MODULATORS OF ADFP IN THE TREATMENT OF ACNE, SEBORRHEA DERMATITIS OR HYPERSEBORRHEA |
US9388112B2 (en) | 2010-01-06 | 2016-07-12 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
WO2012139039A2 (en) | 2011-04-08 | 2012-10-11 | British Columbia Cancer Agency Branch | Bisphenol compounds and methods for their use |
WO2013028572A1 (en) | 2011-08-19 | 2013-02-28 | British Columbia Cancer Agency Branch | Fluorinated bisphenol ether compounds and methods for their use |
RU2684315C2 (en) * | 2011-11-01 | 2019-04-05 | Валиркс Плк | Medical application |
WO2013064830A3 (en) * | 2011-11-01 | 2013-08-22 | Valirx Plc | Medical use |
WO2013064830A2 (en) * | 2011-11-01 | 2013-05-10 | Valirx Plc | Medical use |
JP2018012723A (en) * | 2011-11-01 | 2018-01-25 | ヴァリレックス・ピーエルシー | Medical use |
JP2015505814A (en) * | 2011-11-01 | 2015-02-26 | ヴァリレックス・ピーエルシー | Medical use |
US10023612B2 (en) | 2011-11-01 | 2018-07-17 | Valirx Plc | Method of treating endometriosis |
US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
US10400008B2 (en) | 2013-05-01 | 2019-09-03 | Cancer Research Technology Limited | Modulators of the SRC-kinase activity for preventing or treating metastatic cancer |
US9173939B2 (en) | 2013-05-10 | 2015-11-03 | The University Of British Columbia | Ester derivatives of androgen receptor modulators and methods for their use |
US9375496B2 (en) | 2013-09-09 | 2016-06-28 | British Columbia Cancer Agency Branch | Halogenated compounds for cancer imaging and treatment and methods for their use |
US9682933B2 (en) | 2014-05-30 | 2017-06-20 | British Columbia Cancer Agency Branch | Androgen receptor modulators and methods for their use |
US10071962B2 (en) | 2014-05-30 | 2018-09-11 | British Columbia Cancer Agency Branch | Androgen receptor modulators and methods for their use |
WO2015184393A1 (en) | 2014-05-30 | 2015-12-03 | British Columbia Cancer Agency Branch | Androgen receptor modulators and methods for their use |
US11345670B2 (en) | 2015-01-13 | 2022-05-31 | The University Of British Columbia | Heterocyclic compounds for cancer imaging and treatment and methods for their use |
US10654811B2 (en) | 2015-01-13 | 2020-05-19 | The University Of British Columbia | Heterocyclic compounds for cancer imaging and treatment and methods for their use |
EP3988541A1 (en) | 2015-01-13 | 2022-04-27 | British Columbia Cancer Agency Branch | Heterocyclic compounds for cancer imaging and treatment and methods for their use |
WO2016112455A1 (en) | 2015-01-13 | 2016-07-21 | British Columbia Cancer Agency Branch | Heterocyclic compounds for cancer imaging and treatment and methods for their use |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
US11779550B2 (en) | 2015-03-12 | 2023-10-10 | The University Of British Columbia | Bisphenol ether derivatives and methods for using the same |
WO2017177307A1 (en) | 2016-04-15 | 2017-10-19 | British Columbia Cancer Agency Branch | Bisphenol derivatives and their use as androgen receptor activity modulators |
US11919874B2 (en) | 2016-04-15 | 2024-03-05 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
US11142508B2 (en) | 2016-04-15 | 2021-10-12 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
CN110072879B (en) * | 2016-08-08 | 2023-03-10 | 奥利通公司 | Androgen receptor antisense oligonucleotide |
CN110072879A (en) * | 2016-08-08 | 2019-07-30 | 奥利通公司 | Androgen receptor antisense oligonucleotides |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
US11059795B2 (en) | 2018-10-18 | 2021-07-13 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
US11518747B2 (en) | 2020-04-17 | 2022-12-06 | Essa Pharma, Inc. | Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof |
US11358938B2 (en) | 2020-04-17 | 2022-06-14 | Essa Pharma, Inc. | Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof |
US11242324B2 (en) | 2020-04-17 | 2022-02-08 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
US11814357B2 (en) | 2020-04-17 | 2023-11-14 | Essa Pharma Inc. | Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof |
WO2023046283A1 (en) | 2021-09-22 | 2023-03-30 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity |
WO2023061723A1 (en) | 2021-09-22 | 2023-04-20 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Hydroxyphenyl-ethynyl-phenol derivatives as ar (androgen receptor) transcriptional activity modulators for use in the treatment of i.a. prostate cancer |
Also Published As
Publication number | Publication date |
---|---|
CA2302169A1 (en) | 2000-01-13 |
WO2000001813A3 (en) | 2000-04-13 |
AU4494399A (en) | 2000-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000001813A2 (en) | Peptide inhibitors of androgen-independent activation of androgen receptor | |
Rishi et al. | Estradiol regulation of the human retinoic acid receptor α gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs | |
US5639616A (en) | Isolated nucleic acid encoding a ubiquitous nuclear receptor | |
Forman et al. | c-erbA protooncogenes mediate thyroid hormone-dependent and independent regulation of the rat growth hormone and prolactin genes | |
US5854202A (en) | Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same | |
US7329728B1 (en) | Ligand activated transcriptional regulator proteins | |
US6680368B1 (en) | Estrogen receptor beta | |
Chang et al. | Molecular cloning of new human TR2 receptors: a class of steroid receptor with multiple ligand-binding domains | |
CA2223717A1 (en) | Modified steroid hormones for gene therapy and methods for their use | |
Guiochon-Mantel et al. | Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors. | |
Cavailles et al. | Cathepsin D gene of human MCF7 cells contains estrogen-responsive sequences in its 5′ proximal flanking region | |
Horowitz et al. | Characterization of the domain structure of chick c-erbA by deletion mutation: in vitro translation and cell transfection studies | |
Krett et al. | Human progesterone A-receptors can be synthesized intracellularly and are biologically functional | |
JPH08512197A (en) | Method for screening receptor agonist | |
CA2269642A1 (en) | Modified glucocorticoid receptors, glucocorticoid receptors/progesterone receptors hybrids | |
Govindan et al. | Human glucocorticoid receptor gene promotor—homologous down regulation | |
WO1993008213A1 (en) | Novel physiologically active substance epimorphine, gene which codes for same, and antibody against epimorphine | |
CA2222562A1 (en) | Method for screening for receptor agonists and antagonists | |
Cato et al. | Different regions of the estrogen receptor are required for synergistic action with the glucocorticoid and progesterone receptors | |
Traish et al. | Loss of expression of a 55 kDa nuclear protein (nmt55) in estrogen receptor-negative human breast cancer | |
Cato et al. | Regulation of gene expression by steroid hormones | |
JP2004524371A (en) | Introduction of peptide nucleic acid into cell nucleus via nuclear receptor | |
US5571791A (en) | Modified polypeptide fragments of the glucocorticoid receptor | |
De Vos et al. | Human androgen receptor expressed in HeLa cells activates transcription in vitro | |
Teng | Lactoferrin gene promoter in human and mouse: Analogous and dissimilar characteristics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Kind code of ref document: A Ref document number: 2302169 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09515886 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase |